Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Ulocuplumab |
| Trade Name | |
| Synonyms | BMS-936564|MDX1338 |
| Drug Descriptions |
Ulocuplumab (BMS-936564) is a monoclonal antibody that binds to CXCR4 and prevents binding of SDF-1 (CXCL12), potentially resulting in increased apoptosis and decreased migration of tumor cells (PMID: 23213054, PMID: 31672767). |
| DrugClasses | CXCR4 Inhibitor 15 |
| CAS Registry Number | 1375830-34-4 |
| NCIT ID | C95755 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bortezomib + Dexamethasone + Ulocuplumab | Bortezomib Dexamethasone Ulocuplumab | 0 | 1 |
| Cytarabine + Ulocuplumab | Cytarabine Ulocuplumab | 0 | 1 |
| Dexamethasone + Lenalidomide + Ulocuplumab | Dexamethasone Lenalidomide Ulocuplumab | 0 | 1 |
| Ibrutinib + Ulocuplumab | Ibrutinib Ulocuplumab | 0 | 1 |
| Ulocuplumab | Ulocuplumab | 0 | 1 |